Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Jana Skřičková (Brno, Czech Republic), Jana Skricková, Zbynek Bortlicek, Karel Hejduk, Milos Pesek, Vitezslav Kolek, Marcela Tomiskova, Ivona Grygarkova, Leona Koubkova, Marketa Cernovska, Jaromir Roubec, Frantisek Salajka, Milada Zemanova, Helena Coupkova, Monika Satankova, Milosalav Marel. Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC). Eur Respir J 2016; 48: Suppl. 60, 4839

Member's Comments

No comment yet.

Related content which might interest you: Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Treatment of advanced non-small cell lung cancer with trofosfamide Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 Does consolidation chemotherapy improves survival for locally advanced non-small-cell lung cancer patients receiving concurrent chemoradiotherapy? Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 A phase III randomised trial testing chemotherapy in extensive small-cell lung cancer (SCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Clinical outcome of S-1 monotherapy in patients with advanced non-small cell lung cancer after treatment of pemetrexed Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Ifosfamide (IFO) is a valuable alternative to cisplatin (CDDP) for first-line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC): A meta-analysis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 The prognostic significance of thrombocytopenia during chemotherapy in patients with advanced non-small cell lung cancer Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016 Surgical treatment outcomes on early-stages of non-small-cell lung cancer Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Poor prognostic factors in advanced pulmonary adenocarcinoma patients receiving first-line gefitinib Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Chemotherapy in elderly patients with non-small-cell lung cancer in Tunisian respiratory department Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Accelereated hyperfractionated radiotherapy with uneven crushing daily dose in chemoradiation treatment of inoperable non-small cell lung cancer Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Is there a difference in response to first line chemotherapy related to age in patients with locally advanced or metastatic non-small lung cancer? Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Mortality in asymptomatic vs. symptomatic patients surgically treated for non-small cell lung cancer (NSCLC) Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013 Outcomes of radical treatment of early stage non-small cell lung cancer Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Algorithm of preoperative N-staging of non-small cell lung cancer Source: Annual Congress 2013 –Oncological thoracic surgery Year: 2013